Company Overview and News

 
Bourse surprises with ‘dizzying rally’

2018-09-21 bworldonline
THE PHILIPPINE STOCK EXCHANGE index (PSEi) exited bear territory on Friday amid what one analyst described as “a dizzying rally”, but its strong recovery was not enough to prevent its third straight week-on-week drop.
FPHPC MPCIY BDOUY AYAAY UVRBY AEV FPHP DD SECB MRAIF BDOUF BDO ABTZY MPI MPCFF SYBJF URC MRC ALI FPH UVRBF AYAAF

 
Infracorp plans monorail project linking Eastwood City to MRT-3

2018-09-18 bworldonline
INFRACORP Development, Inc. looks to propose a monorail project connecting the Metro Rail Transit Line 3 (MRT-3) to Eastwood City, in a bid to ease traffic congestion and increase connectivity for commuters in the area.
FILIY JGSMY ALGGY JGS MPCFF MPCIY MPI ALGGF FDC AGI JGSHF

 
AC expects delivery platform to boost logistics business

2018-09-17 bworldonline
AYALA CORP. (AC) aims to grow its newly formed Entrego delivery platform into one of the leading third-party logistics players in the future, as the conglomerate further ramps up its investments in the country’s booming logistics sector.
AC GLO MPCFF MPCIY MPI GTMEY GTMEF GLOPP GLOPA

 
Maynilad wins P5.73/cu.m. tariff hike

2018-09-14 bworldonline
MAYNILAD Water Services, Inc. has obtained an increase of P5.73 per cubic meter (cu. m.) in water tariffs for Metro Manila’s west zone, which the company is offering to impose on a staggered basis.
DMC MWC MPCFF MPCIY MPI DMCIF DMCHY DMCP

 
Maynilad wins tariff hike of P5.73 per cubic meter

2018-09-14 bworldonline
MAYNILAD Water Services, Inc. has obtained an increase of P5.73 per cubic meter (cu. m.) in water tariffs for Metro Manila’s west zone, which the company is offering to impose on a staggered basis.
DMC MWC MPCFF MPCIY MPI DMCIF DMCHY DMCP

 
NAIA consortium’s P102-B proposal gains ground

2018-09-13 bworldonline
A CONSORTIUM composed of seven of the country’s biggest conglomerates has been given original proponent status (OPS) by the government for its P102-billion proposal to rehabilitate and expand the Ninoy Aquino International Airport (NAIA).
JGSMY JGS MPCIY GMQRY GMRINFRA 532754 FILIY ALGGY MWP MPI MPCFF ALGGF FDC AGI MWIDE JGSHF

 
AirAsia joins consortium for Clark O&M bid

2018-09-10 bworldonline
AIRASIA Group Bhd. is joining a consortium, which includes Indonesian airport operator PT Angkasa Pura, that will make a bid for the operations and management (O&M) contract for Clark International Airport in Pampanga.
SMCP1 MPCIY GMQRY GMRINFRA SMGBY 532754 SMGBF FILIY SMC2B SMC2A SMC SMC2D SMC2C MWP MPI MPCFF SMC2F SMC2E FDC MWIDE

 
Razon’s ICTSI cornering biggest stake in busiest domestic port

2018-09-06 business.inquirer.net
Billionaire Enrique Razon Jr.’s International Container Terminal Services Inc. (ICTSI) is increasing its stake in Manila North Harbor Port Inc. to 50 percent—a deal that would make ICTSI the single largest shareholder in the country’s biggest domestic port.
ICT SVTMF PSKXF SMCP1 MPCIY SM ICTEF SMGBY SMGBF SMC2B SMIVY SMC2A SMC SMC2D SMC2C MPI MPCFF SMC2F SMC2E PHSXY PSE

 
Group says no subsidy in Naia rehab offer

2018-09-05 business.inquirer.net
A consortium formed by seven of the country’s biggest conglomerates insisted on Wednesday that it was not seeking any government guarantees, the existence of which could jeopardize its offer to modernize and operate Manila’s Ninoy Aquino International Airport (Naia) for 15 years.
JGSMY JGS MPCIY AEV FILIY ALGGY ABTZY MPI MPCFF ALGGF FDC AGI JGSHF

 
NAIA consortium says proposed terminal fee hike is not a ‘gov’t guarantee’

2018-09-05 bworldonline
THE CONSORTIUM proposing to rehabilitate the Ninoy Aquino International Airport (NAIA) on Wednesday said it is not seeking any government guarantees in its bid to develop and expand the gateway.
FILIY JGSMY ALGGY JGS MPCFF MPCIY MPI ALGGF FDC AGI JGSHF

 
MPTC to use Egis toll collection system

2018-08-31 business.inquirer.net
The toll road arm of Metro Pacific Investments Corp. has tapped France’s Egis Projects to provide the toll collection system for a new expressway south of Metro Manila.
MPCFF MPCIY MPI

 
Ayala unit, Zalora affiliate forming holding firm for logistics business

2018-08-31 business.inquirer.net
Conglomerate Ayala Corp. has firmed up a deal to create an investment holding company for the logistics business in partnership with German firm Brillant 1257 GmbH & Co. Vierte Verwaltungs Kg, an affiliate of e-commerce platform Zalora.
SMIVY PSKXF SVTMF MPCFF MPCIY MPI PHSXY SM PSE

 
PH stocks up in subdued trade

2018-08-30 business.inquirer.net
The benchmark Philippine Stock Exchange index closed in positive territory Thursday even as regional equities saw mixed results on lingering trade tensions between the United States and China.
ICT GTCAP GTCXY SVTMF BDOUY SM ICTEF SECB BDOUF SMIVY MPCFF PHSXY PSE SPHXF SPHZF AYAAF PSKXF MPCIY AYAAY SMPH BDO MPI SPHXY SYBJF ALI

 
Shares slump as market consolidates after rally

2018-08-29 bworldonline
SHARES SLUMPED on Wednesday as the local market paused for a break after rallying past the 7,800 level in previous days.
GTCAP GTCXY SMCP1 RBNTF AEV SMGBF SMC MPCFF RRETY PHSXY PSE RRHI PSKXF MPCIY SMGBY SMC2B SMC2A SMC2D SMC2C ABTZY MPI SMC2F SMC2E BBRRF BLOOM

 
DoTr asks NLEX to drop arbitration case

2018-08-28 bworldonline
THE Department of Transportation (DoTr) is asking NLEX Corp. to drop its arbitration case over long overdue toll fee adjustments at the North Luzon Expressway (NLEx).
PX MPCFF MPCIY MPI PXMFF PXMFY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 59164L200